BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 16270320)

  • 1. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
    Ory B; Heymann MF; Kamijo A; Gouin F; Heymann D; Redini F
    Cancer; 2005 Dec; 104(11):2522-9. PubMed ID: 16270320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
    Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model.
    Koto K; Horie N; Kimura S; Murata H; Sakabe T; Matsui T; Watanabe M; Adachi S; Maekawa T; Fushiki S; Kubo T
    Cancer Lett; 2009 Feb; 274(2):271-8. PubMed ID: 18986762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer effects of zoledronic acid against human osteosarcoma cells.
    Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
    J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
    Ryu K; Murata H; Koto K; Horie N; Matsui T; Nishigaki Y; Sakabe T; Takeshita H; Itoi M; Kimura S; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Anticancer Res; 2010 Jul; 30(7):2713-20. PubMed ID: 20683003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
    Ory B; Blanchard F; Battaglia S; Gouin F; Rédini F; Heymann D
    Mol Pharmacol; 2007 Jan; 71(1):333-43. PubMed ID: 17050806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
    Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
    Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis.
    Horie N; Murata H; Nishigaki Y; Matsui T; Segawa H; Nogawa M; Yuasa T; Kimura S; Maekawa T; Fushiki S; Kubo T
    Cancer Lett; 2006 Jul; 238(1):111-8. PubMed ID: 16112430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
    Zarogoulidis K; Boutsikou E; Zarogoulidis P; Eleftheriadou E; Kontakiotis T; Lithoxopoulou H; Tzanakakis G; Kanakis I; Karamanos NK
    Int J Cancer; 2009 Oct; 125(7):1705-9. PubMed ID: 19521984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
    Lamoureux F; Ory B; Battaglia S; Pilet P; Heymann MF; Gouin F; Duteille F; Heymann D; Redini F
    Int J Cancer; 2008 Feb; 122(4):751-60. PubMed ID: 17960623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
    Nagao S; Hattori N; Fujitaka K; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Haruta Y; Murai H; Kohno N
    Hiroshima J Med Sci; 2011 Mar; 60(1):7-9. PubMed ID: 21675041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
    Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.
    Wittrant Y; Lamoureux F; Mori K; Riet A; Kamijo A; Heymann D; Redini F
    Int J Oncol; 2006 Jan; 28(1):261-9. PubMed ID: 16328004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.
    Henk HJ; Kaura S; Teitelbaum A
    J Med Econ; 2012; 15(1):195-204. PubMed ID: 22175657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model.
    Soltau J; Zirrgiebel U; Esser N; Schächtele C; Totzke F; Unger C; Merfort I; Drevs J
    Anticancer Res; 2008; 28(2A):933-41. PubMed ID: 18507039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The backbone of progress--preclinical studies and innovations with zoledronic acid.
    Green JR; Guenther A
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
    Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
    Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient.
    Battaglia S; Dumoucel S; Chesneau J; Heymann MF; Picarda G; Gouin F; Corradini N; Heymann D; Redini F
    J Bone Miner Res; 2011 Oct; 26(10):2439-51. PubMed ID: 21713986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.